Kenvue Inc.
Kenvue Inc. (KVUE) Stock Overview
Explore Kenvue Inc.’s financial performance, market position, analyst ratings, and future outlook.
KVUE Stock Analysis & Investment Overview
Our comprehensive AI-powered analysis of Kenvue Inc. (KVUE) provides investors with deep insights into the stock's performance, growth potential, and market positioning. With a Meyka AI Score of B+, this stock demonstrates moderate investment characteristics based on our advanced machine learning models.
Our forecasting models predict significant price movements, with a 12-month target of $25.66.
Key financial metrics showcase the company's fundamental strength, including a P/E ratio of 38.46 and a market capitalization of 40.7B. These metrics, combined with our AI analysis, provide a comprehensive view for both institutional and retail investors.
Analyst Recommendations
Price Targets
Company Profile
Kenvue Inc. operates as a consumer health company worldwide. The company operates through three segments: Self Care, Skin Health and Beauty, and Essential Health. The Self Care segment offers cough, cold and allergy, pain care, digestive health, smoking cessation, and other products under the Tylenol, Nicorette, and Zyrtec brands. The Skin Health and Beauty segment provides face and body care, hair care, and sun and other care products under the Neutrogena, Aveeno, and OGX brand names. The Essential Health segment offers oral and baby, women's health, and wound care products under the Listerine, Johnson's, Band-Aid, and Stayfree brands. The company was incorporated in 2022 and is headquartered in Skillman, New Jersey. Kenvue Inc. operates as a subsidiary of Johnson & Johnson.
Mr. Thibaut Mongon
22,000
199 Grandview Road, Skillman, NJ
2023